Congenital Neutropenia Treatment: Introduction
Congenital neutropenia occurs when an individual has low levels of neutrophils, a type of white blood cells. Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones such as the vertebrae, ribs, and pelvis.
White blood cells support the body in fighting infections. Neutrophils fight against infection by demolishing harmful fungi, yeast, and bacteria that attack the body. People with congenital neutropenia have a higher risk of developing serious infections. Half of the individuals with cancer who receive chemotherapy develop some level of neutropenia. Neutropenia is a common side-effect in people living with leukemia.
Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=80473
Key Drivers of Global Congenital Neutropenia Treatment Market
The global congenital neutropenia treatment market is anticipated to expand rapidly in the near few years. Introduction of novel therapies and increase in the cases of chemotherapy-induced neutropenia are likely to be major drivers of the congenital neutropenia treatment market. Cancer is a known cause for developing neutropenia.
A rise in the cases of chemotherapy for the treatment of cancer is projected to boost the congenital neutropenia treatment market. Cancer is among the top five causes of death across all age groups around the world.
In 2014, about 1.6 million new cases of cancer were registered in the U.S., and approximately 600,000 individuals died due to the disease. The most common cancers are prostate cancer, cervical cancer, ovarian cancer, leukemia, pancreatic cancer, lung cancer, breast cancer, non-Hodgkin lymphoma, colorectal cancer, and Hodgkin’s disease.
Request COVID Analysis on Congenital Neutropenia Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=80473
Granulocyte -Colony- Stimulating Factor (G-CSF) to be Highly Attractive Segment
In terms of treatment, the global congenital neutropenia treatment market can be classified into antibiotics, granulocyte -colony- stimulating factor (G-CSF), and antifungal drugs
The granulocyte -colony- stimulating factor (G-CSF) segment is expected to account for a major share of the global congenital neutropenia treatment market by 2030, owing to a rise in the utilization of granulocyte -colony- stimulating factor agents in stimulating the creation of granulocyte
Hospital Pharmacies to be Highly Lucrative Segment
Based on distribution channel, the global congenital neutropenia treatment market can be categorized into retail pharmacies, hospital pharmacies, online pharmacies, and others
The hospitals segment is anticipated to account for a major share of the market in the next few years due to a rise in the number of cancer treatment in hospitals
Pre Book Congenital Neutropenia Treatment Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=80473<ype=S
North America to Offer Significant Opportunities in Congenital Neutropenia Treatment Market
In terms of region, the global congenital neutropenia treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America accounted for a significant share of the global market in 2019 owing to favorable healthcare infrastructure, high per capita income, and high rate of adoption of advanced surgeries in the region
The region’s dominance is further attributed to an increase in the demand for therapeutic needs for febrile neutropenia and execution of new regulations for the commercialization and development of biosimilars
The neutropenia treatment market in Asia Pacific is anticipated to expand at a rapid pace during forecast period, due to a rise in the prevalence of different forms of cancer and increase in healthcare awareness
Key Players Operating in Global Congenital Neutropenia Treatment Market
The global congenital neutropenia treatment market is semi-consolidated, with the presence of international and local players. Key players operating in the global congenital neutropenia treatment market are:
Baxter International
Teva Pharmaceutical, Inc.
Amgen
Sanofi
Novartis AG
Teva Pharmaceuticals Industries Ltd.
Biogenomics Limited
Dr. Reddy’s Laboratory Ltd.
Apotex
Intas Pharmaceuticals Ltd.
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision-makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
